RPCEC00000291尚未招募2 期
Safety and Efficacy assessment of Therapeutic Vaccine CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial
Center of Molecular Immunology (CIM)0 个研究点开始时间: 2018年10月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Single Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 79 years（—）
- 性别
- Male
入选标准
- •1. Patients who have signed informed consent.
- •2. Patients who meet the diagnostic criterion of metastatic castration-resistant prostate adenocarcinoma (patient who after receiving surgical or biochemical castration (Testosterone < 50 ng/DL) progresses to a M1 stage corresponding to the IVb phase Of the disease according to the classification proposed by the AJCC in its eighth edition of the 2017 (any T, any N, M1, any grade group, any PSA).
- •3. Asymptomatic or minimally symptomatic patients. (Low pain levels measured by the Brief pain investigational Short Form Scale (BPI-SF) between 0-1 (asymptomatic) and 2-3 (minimally symptomatic) alleviated with acetaminophen or other non-steroidal anti-inflammatory drugs (CUA, 2015).
- •4. Patients with imaging study and clinical documentation to corroborate the existence of metastatic lesions prior to the onset of treatment for their metastatic disease, according to RECIST criteria (version 1.1).
- •5. Patients aged between 18 and 79 years.
- •6. Patients with life expectancy of 6 months or more.
- •7. Patients with functional status according to ECOG = 2.
- •8. Patients with organ and bone marrow functioning defined by the following parameters: Hemoglobin =90 g/L (patients with lower Hb levels should be transfused prior to inclusion), Total leukocyte Count = to 3.0 x 109/L, neutrophil count = 1.5 x 109/L, Platelet count=100 x 109/L, Bilirrubin: Within normal limits for each institution, Glycemia within normal limits for each institution, ALP: Up to 2.5 times the normal upper limit for each institution, GOT/GPT: up to 2.5 times the normal upper limit for each institution, Creatinine: Within normal limits for each institution.
排除标准
- •1. Patients with cerebral metastases, history of primary CNS tumor, uncontrolled convulsions with standard therapy or history of brain vascular accident.
- •2. Patients with bone pain requiring treatment with opioids.
- •3. Patients with previous history of demyelinating or inflammatory diseases of the CNS or peripheral.
- •4. Patients with previous malignant diseases, except skin cancer (non-melanoma), properly treated.
- •5. Patients with acute allergic states, history of severe allergic reactions or autoimmune diseases.
- •6. Patients who are receiving another product in research.
- •7. Patients with a history of allergy attributed to compounds of chemical or biological composition similar to the product under study and/or the proposed Oncoespecífico treatment.
- •8. Patients carrying uncontrolled intercurrent illnesses, including, but not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and psychiatric illnesses that may Limit adherence to test requirements.
- •9. Patients with symptoms at the time of diagnosis.
研究者
相似试验
尚未招募
2 期
Clinical evaluation of VAYU KEELAGA ILAKAM (Internal) with ERUKKATHY THYLAM (External)in the treatment of MUDAKKU VATHAM .CTRI/2018/04/013541Ayothidoss Pandithar Hospital
尚未招募
3 期
Effect of tranexamic acid and aprotinin in absolute blood loss in pediatric neurosurgeryIRCT20200705048023N1Tehran University of Medical Sciences90
招募中
4 期
COMPARISON OF THREE DIFFERENT DOSES OF FENTANYL TO PREVENT HEMODYNAMIC STRESS RESPONSE DURING INTUBATIOCTRI/2016/01/006519GOVERNMENT MEDICAL COLLEGE90
招募中
不适用
Observational study on efficacy and safety of vaccines against the novel coronavirus disease (COVID-19) in hematopoietic stem cell transplantation (HSCT) patient.allo-SCTJPRN-UMIN000043671Fukuoka Blood and Marrow Transplantation Group1,000
进行中（未招募）
4 期
Safety and effectiveness clinical evaluation of the range of injectable hyaluronic acid medical devices in facial aesthetic treatmentModerate to severe peri-oral lines, moderate to severe nasolabial folds, moderate to severe cheeks/cheekbones volume deficit, chin recursionSkin and Connective Tissue DiseasesISRCTN49836437Kylane Laboratoires SA68